Sigurd D. Süssmuth, MD

Therapeutic Area Mental Health, Boehringer Ingelheim International GmbH, Biberach an der Riss, Germany

JCP
BI 1358894 in Patients With Inadequate Antidepressant Response
Original Research

September 3, 2025

No differences were observed between BI 1358894 treatment groups and placebo for primary and secondary endpoints. BI 1358894 was well tolerated with no increase in self-harm or suicidality.
, , , et al

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe